RxDoctor Payments Data

Sung Park, MD

Family Medicine · Warsaw, INNPI 1336116201

Payments from drug & device makers

$941in general payments, 2019–2025

Across 58 payments — averaging $16.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$173
  • Amgen$115
  • Pfizer$69
  • Johnson & Johnson$60
  • Axsome Therapeutics, Inc.$57
  • Inspire Medical Systems, Inc.$51
  • plus $416 from 19 others

What the payments were for

  • Food & beverage$92899%
  • Education$131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$941 in reported general payments places this provider in the 60th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$113,412
Medicare patients
212
Services billed
1,525

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban115$123,614
JardianceEmpagliflozin131$113,116
OzempicSemaglutide90$104,341
TrulicityDulaglutide48$65,567
Trelegy ElliptaFluticasone/Umeclidin/Vilanter70$59,573
ProliaDenosumab28$49,893
JanuviaSitagliptin Phosphate49$44,857
Tresiba Flextouch U-200Insulin Degludec13$24,148
XareltoRivaroxaban23$23,830
MounjaroTirzepatide21$20,964
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog20$19,820
Tresiba Flextouch U-100Insulin Degludec43$19,433
Lantus SolostarInsulin Glargine,hum.Rec.Anlog107$17,734
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$14,787
MyrbetriqMirabegron18$10,740

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$69$123,614115 claims
Boehringer IngelheimJardiance$28$113,116131 claims
Novo NordiskOzempic$173$104,34190 claims
Lilly USA, LLCTrulicity, Mounjaro$13$86,53069 claims
GSKTrelegy Ellipta, Anoro Ellipta, Arnuity Ellipta$12$79,911103 claims
AmgenProlia$115$49,89328 claims
Johnson & JohnsonXarelto$60$23,83023 claims
Astellas Pharma US IncMyrbetriq$14$10,74018 claims
AstraZenecaSymbicort$11$9,21735 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Warsaw

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →